|
Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. |
|
|
|
Consulting or Advisory Role - Merck |
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst) |
Expert Testimony - Medscape/Bayer; Nanobiotix |
Travel, Accommodations, Expenses - Sanofi/Regeneron |
|
|
Honoraria - Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen |
|
|
Employment - Cancer & Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health; Hospital Universitario Virgen del Rocío |
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Novartis; Pierre Fabre |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Virginia Oncology Associates |
Consulting or Advisory Role - Janssen Oncology |
Speakers' Bureau - Genentech; Janssen Oncology |
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen |
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche/Genentech |
|
|
Stock and Other Ownership Interests - Ignyta |
|
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen |
Speakers' Bureau - Amgen; Bayer |
Research Funding - Bayer (Inst) |
Patents, Royalties, Other Intellectual Property - Amgen |
Travel, Accommodations, Expenses - Amgen; Bayer; Roche |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD Oncology |
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Merck KGaA; MSD Oncology |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Novartis; Pfizer; QED Therapeutics; Sanofi; Tolmar |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst) |
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi |
|
|
Consulting or Advisory Role - Amgen (I); Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer; Pfizer; PFIZER (I); Roche; Roche (I) |
Research Funding - Bayer; Janssen; Roche |
Travel, Accommodations, Expenses - Janssen-Cilag; Roche (I) |
|
|
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Merck; NCCN; Nektar; Seagen |
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda |
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer. |